Navigation Links
BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Date:4/6/2017

BIOARRAY Genetics Inc. (BIOARRAY), a clinical-stage molecular diagnostics company, announced the launch of a novel oncology gene panel, BA325, a research and development tool that accelerates drug discovery and development for cancer treatments by providing new information on cancer response to treatments. BA325 contains 32 genes that are currently drug treatment targets, and provides comprehensive information about oncology drug sensitivity and resistance.

BIOARRAY's BA325 RNA-biomarker panel was derived by querying normal organizational phenotypes. This phenotype-based approach identified genes important to epithelial cell organization in a physiologically relevant context. As a result the selected biomarkers have greater utility in testing tumor samples because 251 of the 325 genes identified are novel and not present in nine other commercially available oncology gene panels. While other oncology biomarker panels are proliferation centric, BIOARRAY's genes bring complementary information with diverse interconnected cell signaling pathways beyond proliferation.

"For more than a century pathologists have understood that there is a relationship between the microscopic structure of a tumor and clinical outcome. Even today, physicians use a tumor grading system based on the relative preservation of normal tissue and cell structures as a guide for treatment,” Edward C. Goodwin, CTO of BIOARRAY, said. “BA325 provides a rich source of gene expression patterns showing how tumors deviate from their normal state, and provides novel guidance for drug development and rationale for companion diagnostics for new therapies, including immuno-oncology drugs."

This week at the 2017 Annual Meeting of the American Association for Cancer Research in Washington, DC, BIOARRAY presented recent studies describing details of BA325's cell signaling pathways network coverage and technical validation of the assay.

"Aligning with the Cancer Moonshot program, we're offering evidence-based predictive diagnostics that will benefit cancer patients by providing actionable information about their treatment options. BA325 brings a new perspective to complement current available information on how drugs work or don't work,” Marcia Fournier, CEO and founder of BIOARRAY, said. “We have a highly skilled, growing team working to accelerate oncology drug discovery and development through industry and clinical partnerships.”

The new studies come shortly after funding from private investors in conjunction with Connecticut Innovations, the leading source of financing and ongoing support for Connecticut, and the 2016 election of seasoned executives Pamela Layton as president and executive chairman; and Jim LaFrance as director of the Board of Directors. Most recently, BIOARRAY signed a sponsored research agreement with UCONN Health to perform a final pre-market clinical study on the company's first clinical diagnostic for breast cancer. The company has a growing pipeline with five tests for common chemotherapies a well as immuno-oncology drugs for breast, lung and colon cancers.

More information about BIOARRAY:
http://bioarray.us/

Read the full story at http://www.prweb.com/releases/2017/04/prweb14222577.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PreventionGenetics Receives New York License for Genetic Tests
2. Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered Lives
3. New CAST Issue Paper: "Plant Breeding and Genetics"
4. Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting
5. Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
6. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
7. Preimplantation Genetics Diagnosis Market to Reach $121.50 Million, by 2022, Globally - Allied Market Research
8. Important Information Regarding the Genetics of Alzheimer’s Disease and Dementia Announced by One Million Solutions in Health™
9. Atlas Genetics Raises $35m in Series D Fundraising
10. Ovation Fertility™ Genetics Formed to Provide Accurate and Reliable PGS for IVF Clinics
11. Regeneron Genetics Center and Geisinger Study Finds Life-Threatening Genetic Disorder is Substantially Underdiagnosed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... entrepreneurship within the healthcare and technology sector at their fourth annual Conference where ... featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
Breaking Biology News(10 mins):